Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $263.8 million.

  • Vanda Pharmaceuticals' Cash & Current Investments fell 2957.38% to $263.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $263.8 million, marking a year-over-year decrease of 2957.38%. This contributed to the annual value of $263.8 million for FY2025, which is 2957.38% down from last year.
  • Vanda Pharmaceuticals' Cash & Current Investments amounted to $263.8 million in Q4 2025, which was down 2957.38% from $293.8 million recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Cash & Current Investments registered a high of $501.5 million during Q1 2023, and its lowest value of $263.8 million during Q4 2025.
  • For the 5-year period, Vanda Pharmaceuticals' Cash & Current Investments averaged around $401.8 million, with its median value being $395.3 million (2021).
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Cash & Current Investments surged by 2107.93% in 2021, and later plummeted by 2957.38% in 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Cash & Current Investments (Quarter) stood at $432.8 million in 2021, then grew by 7.87% to $466.9 million in 2022, then dropped by 16.83% to $388.3 million in 2023, then decreased by 3.51% to $374.6 million in 2024, then fell by 29.57% to $263.8 million in 2025.
  • Its Cash & Current Investments was $263.8 million in Q4 2025, compared to $293.8 million in Q3 2025 and $325.6 million in Q2 2025.